The team's findings were published in the paper "Functional reprogramming of neutrophils within the brain tumor ...

ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...

When they compared the genes in the hypoxia-response signature of normal cells to that of different cancer cells, they found that they were able to classify different tumors by their hypoxia response.

Scientists have discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling further tumor growth.

Tumor hypoxia is known to be associated with a reduction in radio-response. [85,86] The EORTC is now planning a randomized Phase III study [107] in patients with locally advanced HPV/p16-negative ...

Panelists discuss how combining systemic therapy with locoregional treatments like transarterial chemoembolization (TACE) aims to enhance therapeutic efficacy by addressing its limitations, such as ...

ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...

“This trial marks an exciting step forward in addressing one of the key challenges in cancer immunotherapy. Hypoxia limits T-cell infiltration and suppresses immune responses, especially in ...